Drug Development of Therapeutic Monoclonal Antibodies

BioDrugs

Volumn 30, Issue 4, 2016, Pages 275-293

  Mould, Diane R ^a   Meibohm, Bernd ^b  

^a Projections Research Inc   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEMTUZUMAB; BASILIXIMAB; BEVACIZUMAB; CANAKINUMAB; CETUXIMAB; CYCLOSPORIN; DACLIZUMAB; DEXAMETHASONE; DRUG ANTIBODY; DRUG METABOLIZING ENZYME; ECULIZUMAB; EFALIZUMAB; ELOTUZUMAB; HEPARIN; IPILIZUMAB; LENALIDOMIDE; METHOTREXATE; MONOCLONAL ANTIBODY; OMALIZUMAB; PALIFERMIN; PALIVIZUMAB; PANITUMUMAB; PREDNISONE; RAPAMYCIN; RITUXIMAB; SIMVASTATIN; TOCILIZUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ADVANCED CANCER; ALLOMETRY; ANALYTIC METHOD; ANTIGEN ANTIBODY COMPLEX; ASSAY; BIACORE ASSAY; BINDING AFFINITY; BINDING KINETICS; BREAST METASTASIS; CANCER GRAFT; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; CYTOKINE RESPONSE; DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG SAFETY; END STAGE RENAL DISEASE; FLUORESCENCE ACTIVATED CELL SORTING; FOCAL GLOMERULOSCLEROSIS; HUMAN; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; KINEXA; MILD HEPATIC IMPAIRMENT; MODERATE HEPATIC IMPAIRMENT; MULTIPLE MYELOMA; MULTIPLE SCLEROSIS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; NONHUMAN; ORTHOLOGY; PHARMACODYNAMICS; POLYPHARMACY; PRACTICE GUIDELINE; PREDICTION; PRIORITY JOURNAL; PROTEIN LOSING GASTROENTEROPATHY; RECEPTOR OCCUPANCY; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SEVERE RENAL IMPAIRMENT; SKIN TOXICITY; STOMACH CANCER; SURFACE PLASMON RESONANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET MEDIATED DRUG DISPOSITION; TUMOR GROWTH; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG INTERACTION; NORMAL HUMAN; PRECLINICAL STUDY; PROCEDURES; TOXICITY TESTING;

ANIMALS; ANTIBODIES, MONOCLONAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; HEALTHY VOLUNTEERS; HUMANS; TOXICITY TESTS;

EID: 84976293596     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.1007/s40259-016-0181-6     Document Type: Review

References (140)

1. Cragg MS, French RR, Glennie MJ. Signaling antibodies in cancer therapy. Curr Opin Immunol. 1999;11(5):541–7.
2. Mould DR. Using pharmacometrics in the development of biological therapeutic biological agents. In: Ette E, Williams P, editors. Pharmacometrics: the science of quantitative pharmacology. Hoboken: Wiley; 2007. p. 993–1033
3. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147–57.
4. Natsume A, In M, Takamura H, Nakagawa T, Shimizu Y, Kitajima K, et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res. 2008;68:3863–72.
5. Ricart AD, Tolcher AW. Technology insight: cytotoxic drug immunoconjugates for cancer therapy. Nat Clin Pract Oncol. 2007;4(4):245–55.
6. Brennan FR, Morton LD, Spindeldreher S, Kiessling A, Allenspach R, Hey A, et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. MAbs. 2010;2(3):233–55.
7. Wordell CJ. Biotechnology update. Hosp Pharm. 1991;26:897–900.
8. Ortho Pharmaceutical Corporation. OKT3. Summary basis of approval of muromonab-CD3. Freedom of Information Services, FDA; 1986.
9. Pavlovic D, Patera AC, Nyberg F, Gerber M, Liu M; Progressive Multifocal Leukeoncephalopathy Consortium. Progressive multifocal leukoencephalopathy: current treatment options and future perspectives. Ther Adv Neurol Disord. 2015;8(6):255–73.
10. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med. 2006;355:1018–28.
11. ICH. Guidance for industry. S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals. 1997 Jul. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm074957.pdf. Accessed 7 Jan 2016.
12. ICH. Guidance for industry. S6 addendum to preclinical safety evaluation of biotechnology-derived pharmaceuticals. 2012 May. http://www.fda.gov/downloads/Drugs/…/Guidances/UCM194490.pdf. Accessed 7 Jan 2016.
13. Chaparro-Riggers J, Liang H, DeVay RM, Bai L, Sutton JE, Chen W, et al. Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9. J Biol Chem. 2012;287(14):11090–7.
14. Säfsten P, Klakamp SL, Drake AW, Karlsson R, Myszka DG. Screening antibody-antigen interactions in parallel using Biacore A100. Anal Biochem. 2006;353(2):181–90.
15. Leonard P, Säfsten P, Hearty S, McDonnell B, Finlay W, O’Kennedy R. High throughput ranking of recombinant avian scFv antibody fragments from crude lysates using the Biacore A100. J Immunol Methods. 2007;323(2):172–9.
16. Canziani GA, Klakamp S, Myszka DG. Kinetic screening of antibodies from crude hybridoma samples using Biacore. Anal Biochem. 2004;325(2):301–7.
17. Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Discov. Today. 2007;12:540–7.
18. Chapman K, Pullen N, Graham M, Ragan I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat Rev Drug Discov. 2007;6(2):120–6.
19. Rich RL, Myszka DG. Advances in surface plasmon resonance biosensor analysis. Curr Opin Biotechnol. 2000;11:54–61.
20. Karlsson R, Falt A. Experimental design for kinetic analysis of protein–protein interactions with surface plasmon resonance biosensors. J Immunol Methods. 1997;200:121–33.
21. Morton TA, Myszka DG. Kinetic analysis of macromolecular interactions using surface plasmon resonance biosensors. Methods Enzymol. 1998;295:268–94.
22. Roskos L. Molecular engineering II: antibody affinity (Chapter 7). In: Dubel S, editor. Handbook of therapeutic antibodies. Vol. 1. Weinheim: Wiley–VCH; 2007. pp. 45–169.
23. Drake AW, Tang ML, Papalia GA, Landes G, Haak-Frendscho M, Klakamp SL. Biacore surface matrix effects on the binding kinetics and affinity of an antigen/antibody complex. Anal Biochem. 2012;429(1):58–69.
24. Drake AW, Myszka DG, Klakamp SL. Characterizing high-affinity antigen/antibody complexes by kinetic- and equilibrium-based methods. Anal. Biochem. 2004;328:35–43.
25. Blake RC 2nd, Pavlov AR, Blake DA. Automated kinetic exclusion assays to quantify protein binding interactions in homogeneous solution. Anal Biochem. 1999;272(2):123–34.
26. Darling RJ, Brault P-A. Kinetic exclusion assay technology: characterization of molecular interactions. Assay Drug Dev Technol. 2004;2:647–57.
27. Mould DR, Davis CB, Minthorn EA, Kwok DC, Elliott MJ, Luggen ME, et al. A population pharmacokinetic-pharmacodynamic analysis of single doses of clenoliximab in patients with rheumatoid arthritis. Clin Pharmacol Ther. 1999;66(3):246–57.
28. Drake AW, Klakamp SL. A rigorous multiple independent binding site model for determining cell-based equilibrium dissociation constants. J Immunol Methods. 2007;318(1–2):147–52.
29. Spilker ME, Singh P, Vicini P. Mathematical modeling of receptor occupancy data: a valuable technology for biotherapeutic drug development. Cytometry B Clin Cytom. 2016;90(2):230–6. doi:10.1002/cyto.b.21318.
30. Bates JT, Keefer CJ, Slaughter JC, Kulp DW, Schief WR, Crowe JE Jr. Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein. Virology. 2014;454–455:139–44.
31. Junghans RP. Finally! The Brambell receptor (FcRB). Mediator of transmission of immunity and protection from catabolism for IgG. Immunol Res. 1997;16(1):29–57.
32. Glassman PM, Balthasar JP. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med. 2014;11(1):20–33.
33. European Medicinal agency (EMEA). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins (Doc. Ref. EMEA/CHMP/BMWP/14327/2006). London: EMEA; 2006.
34. De Groot AS, Moise L. Prediction of immunogenicity for therapeutic proteins: state of the art. Curr Opin Drug Discov Devel. 2007;10(3):332–40.
35. Stas P, Lasters I. Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs. 2009;12(3):169–73.
36. Meibohm B, Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. J Pharm Sci. 2002;91(1):18–31.
37. Gibbs JP. Prediction of exposure-response relationships to support first-in-human study design. AAPS J. 2010;12(4):750–8.
38. Holmdahl R, Lorentzen JC, Lu S, Olofsson P, Wester L, Holmberg J, et al. Arthritis induced in rats with nonimmunogenic adjuvants as models for rheumatoid arthritis. Immunol Rev. 2001;184:184–202.
39. Knoerzer DB, Karr RW, Schwartz BD, Mengle-Gaw LJ. Collagen-induced arthritis in the BB rat. Prevention of disease by treatment with CTLA-4-Ig. J Clin Invest. 1995;96(2):987–93.
40. Lon HK, Liu D, DuBois DC, Almon RR, Jusko WJ. Modeling pharmacokinetics/pharmacodynamics of abatacept and disease progression in collagen-induced arthritic rats: a population approach. J Pharmacokinet Pharmacodyn. 2013;40(6):701–12.
41. Lon HK, Liu D, Zhang Q, DuBois DC, Almon RR, Jusko WJ. Pharmacokinetic-pharmacodynamic disease progression model for effect of etanercept in Lewis rats with collagen-induced arthritis. Pharm Res. 2011;28(7):1622–30.
42. Earp JC, Dubois DC, Almon RR, Jusko WJ. Quantitative dynamic models of arthritis progression in the rat. Pharm Res. 2009;26(1):196–203.
43. Dong JQ, Salinger DH, Endres CJ, Gibbs JP, Hsu CP, Stouch BJ, et al. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction. Clin Pharmacokinet. 2011;50(2):131–42.
44. Roy A, Mould DR, Wang XF, Tay L, Raymond R, Pfister M. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. J Clin Pharmacol. 2007;47(11):1408–20.
45. Lute KD, May KF Jr, Lu P, Zhang H, Kocak E, Mosinger B, et al. Human CTLA4 knock-in mice unravel the quantitative link between tumor immunity and autoimmunity induced by anti-CTLA-4 antibodies. Blood. 2005;106(9):3127–33.
46. Lee H, Zahra D, Vogelzang A, Newton R, Thatcher J, Quan A, et al. Human C5aR knock-in mice facilitate the production and assessment of anti-inflammatory monoclonal antibodies. Nat Biotechnol. 2006;24(10):1279–84.
47. Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs. 1999;17(4):343–59.
48. Hood JD, Cheresh DA. Building a better Trap. Proc Natl Acad Sci USA. 2003;100(15):8624–5.
49. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407(6801):249–57.
50. Carmeliet P, Jain RK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov. 2011;10(6):417–27.
51. Wartha K, Herting F, Hasmann M. Fit-for purpose use of mouse models to improve predictivity of cancer therapeutics evaluation. Pharmacol Ther. 2014;142(3):351–61.
52. Loisel S, Ohresser M, Pallardy M, Daydé D, Berthou C, Cartron G, et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol. 2007;62(1):34–42.
53. Ribba B, Holford NH, Magni P, Trocóniz I, Gueorguieva I, Girard P, et al. A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis. CPT Pharmacometrics Syst Pharmacol. 2014;7(3):e113. doi:10.1038/psp.2014.12.
54. Daydé D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H, et al. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood. 2009;113(16):3765–72.
55. Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet. 1999;354(9191):1691–5.
56. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, et al. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007;30(8):825–30.
57. Bria E, Cuppone F, Milella M, Verma S, Carlini P, Nistico C, et al. Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin Biol Ther. 2008;8:1963–71.
58. Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, et al. Preclinical development of monoclonal antibodies: considerations for the use of non-human primates. MAbs. 2009;1(5):505–16.
59. Schweiterman W. Regulating biopharmaceuticals under CDER versus CBER: an insider’s perspective. Drug Discov Today. 2006;11:945–51.
60. Ober RJ, Radu CG, Ghetie V, Ward ES. Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. Int Immunol. 2001;13(12):1551–9.
61. Deng R, Iyer S, Theil FP, Mortensen DL, Fielder PJ, Prabhu S. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned? MAbs. 2011;3(1):61–6.
62. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J. 2012;14(2):296–302.
63. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. Rockville: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2005.
64. Lowe PJ, Tannenbaum S, Wu K, Lloyd P, Sims J. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models. Basic Clin Pharmacol Toxicol. 2010;106(3):195–209.
65. Muller PY, Milton M, Lloyd P, Sims J, Brennan FR. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Opin Biotechnol. 2009;20(6):722–9.
66. Tabares P, Berr S, Romer PS, Chuvpilo S, Matskevich AA, Tyrsin D, et al. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08. Eur J Immunol. 2014;44(4):1225–36.
67. Nolting A, Fox F, Kovar A. Clinical drug development of cetuximab, a monoclonal antibody. In: Meibohm B, editor. Pharmacokinetics and pharmacodynamics of biotech drugs. Weinheim: Wiley-VCH; 2006. p. 353–71.
68. Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol. 2009;49(9):1012–24.
69. Dirks NL, Nolting A, Kovar A, Meibohm B. Population pharmacokinetics of cetuximab in patients with squamous cell carcinoma of the head and neck. J Clin Pharmacol. 2008;48(3):267–78.
70. Mould DR, Green B. Pharmacokinetics and pharmacodynamics of monoclonal antibodies: concepts and lessons for drug development. BioDrugs. 2010;24(1):23–39.
71. Fasanmade AA, Adedokun OJ, Olson A, Strauss R, Davis HM. Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis. Int J Clin Pharmacol Ther. 2010;48(5):297–308.
72. Rosario M, Dirks NL, Gastonguay MR, Fasanmade AA, Wyant T, Parikh A, et al. Population pharmacokinetics-pharmacodynamics of vedolizumab in patients with ulcerative colitis and Crohn’s disease. Aliment Pharmacol Ther. 2015;42(2):188–202.
73. Lu JF, Bruno R, Eppler S, Novotny W, Lum B, Gaudreault J. Clinical pharmacokinetics of bevacizumab in patients with solid tumors. Cancer Chemother Pharmacol. 2008;62:779–86.
74. ® prescribing information. South San Francisco: Genentech, Inc.; 2014.
75. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin Drug Deliv. 2007;4(4):427–40.
76. Tang L, Persky AM, Hochhaus G, Meibohm B. Pharmacokinetic aspects of biotechnology products. J Pharm Sci. 2004;93(9):2184–204.
77. Zhao L, Ji P, Li Z, Roy P, Sahajwalla CG. The antibody drug absorption following subcutaneous or intramuscular administration and its mathematical description by coupling physiologically based absorption process with the conventional compartment pharmacokinetic model. J Clin Pharmacol. 2013;53(3):314–25.
78. Gill KL, Gardner I, Li L, Jamei M. A bottom-up whole-body physiologically based pharmacokinetic model to mechanistically predict tissue distribution and the rate of subcutaneous absorption of therapeutic proteins. AAPS J. 2016;18(1):156–70.
79. Tranter E, Peters G, Boyce M, Warrington S. Giving monoclonal antibodies to healthy volunteers in phase 1 trials: is it safe? Br J Clin Pharmacol. 2013;76(2):164–72.
80. Tosi D, Laghzali Y, Vinches M, Alexandre M, Homicsko K, Fasolo A, et al. Clinical development strategies and outcomes in first-in-human trials of monoclonal antibodies. J Clin Oncol. 2015;33(19):2158–65.
81. Cherin P, Marie I, Michallet M, Pelus E, Dantal J, Crave JC, et al. Management of adverse events in the treatment of patients with immunoglobulin therapy: a review of evidence. Autoimmun Rev. 2016;15(1):71–81.
82. Zhang X, Brennan BJ. Disease-drug-drug interaction assessment for tocilizumab—a monoclonal antibody against interleukin-6 receptor to treat patients with rheumatoid arthritis. In: Zhou H, Meibohm B, editors. Drug-drug interactions for therapeutic biologics. Hoboken: Wiley; 2013. p. 191–205.
83. Zhou H, Meibohm B. Drug-drug interactions for therapeutic biologics. Hoboken: Wiley; 2013.
84. Schmitt C, Kuhn B, Zhang X, Kivitz AJ, Grange S. Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis. Clin Pharmacol Ther. 2011;89(5):735–40.
85. Lu D, Girish S, Theil FP, Joshi A. Pharmacokinetic and pharmacodynamic based drug interactions for therapeutic proteins. In: Zhou H, Meibohm B, editors. Drug-drug interactions for therapeutic biologics. Hoboken: Wiley; 2013. p. 5–37.
86. Joshi A, Bauer R, Kuebler P, White M, Leddy C, Compton P, et al. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis. J Clin Pharmacol. 2006;46(1):10–20.
87. Seitz K, Zhou H. Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check. J Clin Pharmacol. 2007;47(9):1104–18.
88. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66(7):921–6.
89. Wijngaarden S, van Roon JA, van de Winkel JG, Bijlsma JW, Lafeber FP. Down-regulation of activating Fcgamma receptors on monocytes of patients with rheumatoid arthritis upon methotrexate treatment. Rheumatology. 2005;44(6):729–34.
90. Yang BB, Gillespie B, Smith B, Smith W, Lissmats A, Rudebeck M, et al. Pharmacokinetic and pharmacodynamic interactions between palifermin and heparin. J Clin Pharmacol. 2015;55(10):1109–18.
91. DHHS, Food and Drug Administration. Guidance for industry: drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. Silver Spring: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 2012.
92. Rathi C, Meibohm B. Clinical pharmacology of bispecific antibody constructs. J Clin Pharmacol. 2015;55 (Suppl 3):S21–8.
93. Meibohm B, Zhou H. Characterizing the impact of renal impairment on the clinical pharmacology of biologics. J Clin Pharmacol. 2012;52(1 Suppl):54S–62S.
94. Zhang Y, Yao Z, Kaila N, Kuebler P, Visich J, Maia M, et al. Pharmacokinetics of ranibizumab after intravitreal administration in patients with retinal vein occlusion or diabetic macular edema. Ophthalmology. 2014;121(11):2237–46.
95. Berdeja J, Jagannath S, Zonder J, Badros A, Kaufman JL, Manges R, et al. Pharmacokinetics and safety of elotuzumab combined with lenalidomide and dexamethasone in patients with multiple myeloma and various levels of renal impairment: results of a phase Ib study. Clin Lymphoma Myeloma Leuk. 2015;16(3):129–38.
96. Roberts BV, Susano I, Gipson DS, Trachtman H, Joy MS. Contribution of renal and non-renal clearance on increased total clearance of adalimumab in glomerular disease. J Clin Pharmacol. 2013;53(9):919–24.
97. Struemper H, Chen C, Cai W. Population pharmacokinetics of belimumab following intravenous administration in patients with systemic lupus erythematosus. J Clin Pharmacol. 2013;53(7):711–20.
98. European Medicines Agency. Guideline on the clinical investigation of the pharmacokinetics of therapeutic proteins. London: European Medicines Agency; 2007.
99. Meibohm B. Pharmacokinetics and pharmacodynamics of peptide and protein therapeutics. In: Crommelin DJA, Sindelar RD, Meibohm B, editors. Pharmaceutical biotechnology: fundamentals and applications. New York: Springer; 2013. p. 101–132
100. Amgen Inc. Vectibix (Panitumumab) prescribing information. Thousand Oaks: Amgen Inc.; 2015.
101. Krens LL, Baas JM, de Jong FA, Guchelaar HJ, Gelderblom H. Pharmacokinetics of panitumumab in a patient with liver dysfunction: a case report. Cancer Chemother Pharmacol. 2014;73(2):429–33.
102. Moosmann N, Laessig D, Michaely HJ, Schulz C, Heinemann V. Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia. Onkologie. 2007;30(10):509–12.
103. Xu Z, Davis HM, Zhou H. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther. 2013;137(2):225–47.
104. Zhang Y, Wei X, Bajaj G, Barrett JS, Meibohm B, Joshi A, et al. Challenges and considerations for development of therapeutic proteins in pediatric patients. J Clin Pharmacol. 2015;55(Suppl 3):S103–15.
105. Pascher A, Pratschke J, Neuhaus P, Tullius SG. Modifications of immune regulations with increasing donor and recipient age. Ann Transplant. 2004;9(1):72–3.
106. Edlund H, Melin J, Parra-Guillen ZP, Kloft C. Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children. Clin Pharmacokinet. 2015;54(1):35–80.
107. Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28(6):507–32.
108. Barrett JS, Della Casa Alberighi O, Laer S, Meibohm B. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin Pharmacol Ther. 2012;92(1):40–9.
109. Laer S, Barrett JS, Meibohm B. The in silico child: using simulation to guide pediatric drug development and manage pediatric pharmacotherapy. J Clin Pharmacol. 2009;49(8):889–904.
110. Falaiye TO, Mitchell KR, Lu Z, Saville BR, Horst SN, Moulton DE, et al. Outcomes following infliximab therapy for pediatric patients hospitalized with refractory colitis-predominant IBD. J Pediatr Gastroenterol Nutr. 2014;58(2):213–9.
111. Mould DR, Baumann A, Kuhlmann J, Keating MJ, Weitman S, Hillmen P, et al. Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol. 2007;64(3):278–91.
112. Garnock-Jones KP. Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis. Drugs. 2014;74(4):489–504.
113. Bernadou G, Campone M, Merlin JL, Gouilleux-Gruart V, Bachelot T, Lokiec F, et al. Influence of tumour burden on trastuzumab pharmacokinetics in HER2 positive non-metastatic breast cancer. Br J Clin Pharmacol. 2016;81(5):941–8. doi:10.1111/bcp.12875.
114. Cosson VF, Ng VW, Lehle M, Lum BL. Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer. Cancer Chemother Pharmacol. 2014;73(4):737–47.
115. Zhou H, Theil F-P, editors. ADME and translational pharmacokinetics/pharmacodynamics of therapeutic proteins: applications in drug discovery and development. Hoboken: Wiley; 2016. p. 129.
116. Kaneshige H. Nonenzymatic glycosylation of serum IgG and its effect on antibody activity in patients with diabetes mellitus. Diabetes. 1987;36(7):822–8.
117. Kapel N, Meillet D, Favennec L, Magne D, Raichvarg D, Gobert JG. Evaluation of intestinal clearance and faecal excretion of alpha 1-antiproteinase and immunoglobulins during Crohn’s disease and ulcerative colitis. Eur J Clin Chem Clin Biochem. 1992;30(4):197–202.
118. Brandse JF, van den Brink GR, Wildenberg ME, van der Kleij D, Rispens T, Jansen JM, et al. Loss of infliximab into feces is associated with lack of response to therapy in patients with severe ulcerative colitis. Gastroenterology. 2015;149(2):350–5.
119. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis. 2010;69(5):817–21.
120. Barbosa MD, Vielmetter J, Chu S, Smith DD, Jacinto J. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol. 2006;118(1):42–50.
121. Ordás I, Mould DR, Feagan BG, Sandborn WJ. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther. 2012;91(4):635–46.
122. Mould DR. The pharmacokinetics of biologics: a primer. Dig Dis. 2015;33(suppl 1):61–9.
123. Mould DR. Why therapeutic drug monitoring is needed for monoclonal antibodies and how do we implement this? Clin Pharmacol Ther. 2016;99(4):351–4. doi:10.1002/cpt.278.
124. Mould DR, Dubinsky MC. Dashboard systems: pharmacokinetic/pharmacodynamic mediated dose optimization for monoclonal antibodies. J Clin Pharmacol. 2015;55(Suppl 3):S51–9.
125. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics: theory and clinical application. Clin Pharmacokinet. 1986;11:387–401.
126. Zhang L, Pfister M, Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J. 2008;10(4):552–9.
127. Mould DR, Upton RN. Basic concepts in population modeling, simulation and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;1:e6.
128. Dirks NL, Meibohm B. Population pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet. 2010;49(10):633–59.
129. Department of Health and Human Services, Office of Inspector General. Challenges to FDA’s ability to monitor and inspect foreign clinical trials. http://oig.hhs.gov/oei/reports/oei-01-08-00510.pdf. Accessed 2 Feb 2016.
130. Chang WC, Midodzi WK, Westerhout CM, Boersma E, Cooper J, Barnathan ES, et al. Are international differences in the outcomes of acute coronary syndromes apparent or real? A multilevel analysis. J Epidemiol Community Health. 2005;59(5):427–33.
131. McGraw J, Waller D. Cytochrome P450 variations in different ethnic populations. Expert Opin Drug Metab Toxicol. 2012;8(3):371–82.
132. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J Rheumatol. 2000;27(4):841–50.
133. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W, et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol. 2008;48(6):681–95.
134. Fasanmade AA, Adedokun OJ, Ford J, Hernandez D, Johanns J, Hu C, et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009;65(12):1211–28.
135. Fasanmade AA, Adedokun OJ, Blank M, Zhou H, Davis HM. Pharmacokinetic properties of infliximab in children and adults with Crohn’s disease: a retrospective analysis of data from 2 phase III clinical trials. Clin Ther. 2011;33(7):946–64.
136. Anasetti C, Hansen JA, Waldmann TA, Appelbaum FR, Davis J, Deeg HJ, et al. Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood. 1994;84(4):1320–7.
137. Mould DR, Sweeney KR. The pharmacokinetics and pharmacodynamics of monoclonal antibodies–mechanistic modeling applied to drug development. Curr Opin Drug Discov Devel. 2007;10(1):84–96.
138. Vincenti F, Lantz M, Birnbaum J, Garovoy M, Mould D, Hakimi J, et al. A phase I trial of humanized anti-interleukin 2 receptor antibody in renal transplantation. Transplantation. 1997;63(1):33–8.
139. Othman AA1, Tran JQ, Tang MT, Dutta S. Population pharmacokinetics of daclizumab high-yield process in healthy volunteers: integrated analysis of intravenous and subcutaneous, single- and multiple-dose administration. Clin Pharmacokinet. 2014;53(10):907–18.
140. Xu Z, Mould D, Hu C, Ford J, Keen M, Davis HM, et al. Population pharmacokinetic analysis of infliximab pediatrics using integrated data from six clinical trials. Clin Pharmacol Drug Dev. 2012;4:203.